Influenza Clinical Trial
Official title:
Influenza A 2009 H1N1 Human Challenge Study in Healthy Adult Volunteers
Background:
- A challenge study exposes a person to a disease and allows researchers to study the
disease through the body's healing process. An influenza challenge study that looks at
different amounts of the flu virus can provide more information on the smallest amount
needed to cause an infection. Researchers want to give one dose of the Influenza A H1N1
virus to healthy volunteers to see how the body responds to the virus.
Objectives:
- To find the smallest dose of Influenza A H1N1 virus that may cause a mild to moderate
flu infection in a healthy adult.
- To study how the body s immune system responds to the virus.
Eligibility:
- Healthy volunteers at least 18 years of age.
- Participants must be willing to remain in isolation for a minimum of 9 days.
Design:
- Participants will be admitted to a hospital inpatient isolation unit. They will be
screened with a physical exam and medical history. They will also have heart and lung
function tests. Blood, urine, and nasal swab/wash samples will be collected.
- Participants will receive a single nasal spray of the flu virus. They will stay on the
inpatient unit for at least 9 days.
- Participants will be monitored for the length of their stay. They will have frequent
blood tests and other procedures as needed.
- Participants will be allowed to go home once they have had two negative tests for the
virus. The tests will be given on two consecutive days....
The high morbidity and mortality associated with both pandemic and seasonal influenza, and
the anticipation of future influenza pandemics, puts influenza front and center in
infectious disease research. Because the natural history and pathogenesis of human influenza
has not been well characterized and cannot be adequately studied in animal models or with
current in vitro techniques, important questions about influenza pathogenesis can only be
approached through human challenge studies.
Previous human challenge studies have addressed some aspects of the natural history of
influenza by evaluating the timing of viral replication, shedding, clinical symptoms, and
innate and adaptive immune responses. Although these studies have provided important
information, in the United States, all but 1 were performed prior to 1990. Without
exception, these studies had limitations due to the scope of the study and/or the scientific
techniques available at that time.
The primary objective of this study is to determine the dose of influenza A 2009 H1N1 human
challenge virus that will induce a mild to moderate uncomplicated influenza infection in
healthy volunteers. This protocol will examine some of the basic questions that remain
unanswered regarding the pathogenesis of influenza in humans, namely, a detailed clinical
and immunological characterization of uncomplicated influenza viral pathogenesis in healthy
adult volunteers.
Secondary objectives will evaluate clinical disease, length of viral shedding, and
pathogenesis in those with influenza infection including identification of clinical markers
of the disease. Notably, the exploratory objectives will seek to discover viral factors
necessary for human infection/adaptation and to evaluate host immune response, viral
replication, viral fitness, and the intrahost evolution.
Collaboration between NIAID investigators and outside scientists will generate opportunities
to further develop and expand areas of clinical influenza research based on the proposed
challenge model.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |